Uncontrolled atopic dermatitis (AD) can have dire, lifelong consequences for children and their families. However, medical science has developed several treatments that target the molecular drivers of …
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
This Expert Illustrations & Commentaries™ is a video-based program in which 2 experts discuss the pathophysiology of atopic dermatitis (AD) with emphasis on the role of OX40 and OX40 ligand …
Highlights from Winter Clinical Hawaii and Winter Clinical Miami: Preventing Pruritus in Atopic Dermatitis: Are Biologics an Answer?
The 45-minute session will be designed to help dermatology providers increase their knowledge and understanding of Atopic Dermatitis. Case examples will be utilized throughout the presentation as …
Expanding the Therapeutic “AHR”senal for Pediatric Atopic Dermatitis
Aryl hydrocarbon receptor (AhR) agonist therapy for pediatric atopic dermatitis (AD) has shown much promise for addressing current treatment challenges with 1) efficacy in reducing atopic lesions and …
Continue Reading about Expanding the Therapeutic “AHR”senal for Pediatric Atopic Dermatitis →
A New Wave of Topical Therapies for Atopic Dermatitis: Comparing Treatment Approaches
Topical therapies are considered the mainstay treatment for atopic dermatitis (AD). However, traditional topicals such as corticosteroids and calcineurin inhibitors are associated with limitations for …
Atopic Dermatitis: Evaluation and Targeted Management
Atopic dermatitis (AD) is a chronic relapsing and remitting inflammatory skin disease that commonly presents in childhood. It is characterized primarily by scaly, pruritic, erythematous lesions …
Continue Reading about Atopic Dermatitis: Evaluation and Targeted Management →
Talking With Your Patients About JAK Inhibitors for Atopic Dermatitis
The goal of this activity is for learners to be better able to discuss risks and benefits of Janus kinase (JAK) inhibitors for patients with moderate-to-severe atopic dermatitis (AD). …
Continue Reading about Talking With Your Patients About JAK Inhibitors for Atopic Dermatitis →
Evolving Targets in Atopic Dermatitis
The goal of this activity is for learners to be better able to contextualize how emerging treatments for AD can be integrated into practice. …
Continue Reading about Evolving Targets in Atopic Dermatitis →
Atopic Dermatitis: Practice Clinician Decision-Making in Virtual Patient Cases
This activity is intended for Dermatologists, Allergists/Immunologists, NPs, and PAs in these specialties who treat patients with atopic dermatitis. The goal of this activity is for clinicians to …
What’s on the Horizon in Atopic Dermatitis? A Focus on OX40-OX40 Ligand-Targeted Therapies
The goal of this activity is for learners to better understand of AD immunopathology and the mechanisms of action (MoAs) of and clinical data on new drugs in development that target the OX40-OX40L …
Prevention is the Best Medicine: ADing up the Data
Atopic Dermatitis (AD) is the second most common chronic inflammatory (coming for you acne!) which unapologetically imparts a tremendous burden on society as a whole. But what if you could jump in the …
Continue Reading about Prevention is the Best Medicine: ADing up the Data →